ALOPECIA TREATMENT MARKET ANALYSIS

Alopecia Treatment Market, By Drug Class (Corticosteroids, 5 AR Inhibitors, Vasodilators, Others), By Disease Type (Alopecia Areata, Androgenic Alopecia, Traction Alopecia, Others), By Route of Administration (Topical, Oral, Injectable Topical application), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023
Code : CMI1847
Pages :193
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Alopecia Treatment Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global alopecia treatment market growth over the forecast period. North America is estimated to hold 35.9% of the market share in 2023 as key players operating in the market are focusing on product launches. For instance, in June 2022, Eli Lilly and Company, a U.S.-based pharmaceutical company, and Incyte, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved OLUMIANT (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), and is available as 4-mg, 2-mg and 1-mg tablets.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa